Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company plc    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC

(PRGO)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
48.11(c) 47.75(c) 48.63(c) 47.93(c) 48.03(c) Last
1 010 648 795 586 856 083 510 085 332 731 Volume
-1.43% -0.75% +1.84% -1.44% +0.21% Change
More quotes
Financials (USD)
Sales 2020 5 123 M - -
Net income 2020 65,6 M - -
Net Debt 2020 2 747 M - -
P/E ratio 2020 73,9x
Yield 2020 1,86%
Sales 2021 5 216 M - -
Net income 2021 318 M - -
Net Debt 2021 2 368 M - -
P/E ratio 2021 18,5x
Yield 2021 2,02%
Capitalization 6 556 M 6 556 M -
EV / Sales 2020 1,82x
EV / Sales 2021 1,71x
Nbr of Employees 11 200
Free-Float 99,3%
More Financials
Company
Perrigo Company plc develops, produces, and sells therapy and care products. Sales break down by product family as follows: - consumable care products (80%). The group also offers medical diagnostic products. Net sales break down by geographical area between the United States/Canada/Mexico (64.3%), Europe and Australia (35,7%); - generic prescription drugs (20%). At the end of 2019, the group has 93 production... 
More about the company
All news about PERRIGO COMPANY PLC
11/25PERRIGO COMPANY PLC : Ex-dividend day for
FA
11/20PERRIGO : 'Quitting is better' Campaign Enters its Fourth Year of Partnership wi..
AQ
11/13Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corpora..
AQ
11/05PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
11/04PERRIGO : 3Q Earnings Snapshot
AQ
11/04PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
AQ
11/04Perrigo loses bid to quash $1.9 bln Irish back tax demand
RE
11/04Irish High Court rejects Perrigo bid to quash 1.6 bln euro back tax bill
RE
10/28PERRIGO : to Build New North American Corporate Headquarters on 'Medical Mile' i..
AQ
09/18Sensex, Nifty end lower as banks drop; pharma shines
RE
09/18Pharma stocks lift Indian markets; Dr.Reddy's hits record high
RE
09/09PERRIGO : Announces the Store Brand Equivalent of Voltaren Arthritis Pain Is Ava..
AQ
09/04Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV C..
AQ
08/27PERRIGO COMPANY PLC : Ex-dividend day for
FA
08/15GLOBAL LEGAL INSIGHTS CORPORATE TAX : Ireland
AQ
More news
News in other languages on PERRIGO COMPANY PLC
2019GLAXOSMITHKLINE : Perrigo achète les droits du Prevacid
2019WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2019Le bénéfice de Johnson & Johnson bondit de 41,8% au deuxième trimestre
2019WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2019Takeda anticipe une perte en 2019-2020 après le rachat de Shire
More news
Analyst Recommendations on PERRIGO COMPANY PLC
More recommendations
Chart PERRIGO COMPANY PLC
Duration : Period :
Perrigo Company plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERRIGO COMPANY PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 54,11 $
Last Close Price 48,03 $
Spread / Highest target 33,3%
Spread / Average Target 12,7%
Spread / Lowest Target -16,7%
EPS Revisions
Managers
NameTitle
Murray S. Kessler President, Chief Executive Officer & Director
Rolf Allan Classon Chairman
Raymond P. Silcock Chief Financial & Accounting Officer
Thomas Farrington Chief Information Officer & Executive VP
Grainne Quinn Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY PLC-7.03%6 556
DAIICHI SANKYO COMPANY, LIMITED56.60%72 682
JIANGSU HENGRUI MEDICINE CO., LTD.17.92%69 850
YUNNAN BAIYAO GROUP CO.,LTD7.23%18 673
ORION OYJ-3.10%6 712
SWEDISH ORPHAN BIOVITRUM AB1.42%5 440